Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: Evidence that they exert tumoricidal effects via tumor tropism (Review)
- Authors:
- Bo-Rim Yi
- Kelvin J. Choi
- Seung U. Kim
- Kyung-Chul Choi
-
Affiliations: Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea, Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada - Published online on: June 20, 2012 https://doi.org/10.3892/ijo.2012.1523
- Pages: 798-804
This article is mentioned in:
Abstract
 |
|
Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar | |
|
Vincent-Salomon A and Thiery JP: Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 5:101–106. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Middleton LP, Tressera F, Sobel ME, Bryant BR, Alburquerque A, Grases P and Merino MJ: Infiltrating micropapillary carcinoma of the breast. Mod Pathol. 12:499–504. 1999.PubMed/NCBI | |
|
Goldstein NS, Vicini FA, Kestin LL and Thomas M: Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age. Cancer. 88:2553–2560. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Li CI, Anderson BO, Porter P, Holt SK, Daling JR and Moe RE: Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 88:2561–2569. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lakhani SR, Audretsch W, Cleton-Jensen AM, Cutuli B, Ellis I, Eusebi V, Greco M, Houslton RS, Kuhl CK, Kurtz J, et al: The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur J Cancer. 42:2205–2211. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cianfrocca M and Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist. 9:606–616. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, et al: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 356:1295–1303. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Skinner KA and Silverstein MJ: The management of ductal carcinoma in situ of the breast. Endocr Relat Cancer. 8:33–45. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Singletary SE and Connolly JL: Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 56:37–50. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J and Bischof M: Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 10:1052010. View Article : Google Scholar : PubMed/NCBI | |
|
Lv H, Pan G, Zheng G, Wu X, Ren H, Liu Y and Wen J: Expression and functions of the repressor element 1 (RE-1)-silencing transcription factor (REST) in breast cancer. J Cell Biochem. 110:968–974. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH and Arun B: BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol. 25:4635–4641. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Olsson H: Tumour biology of a breast cancer at least partly reflects the biology of the tissue/epithelial cell of origin at the time of initiation - a hypothesis. J Steroid Biochem Mol Biol. 74:345–350. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Giordano SH, Cohen DS, Buzdar AU, Perkins G and Hortobagyi GN: Breast carcinoma in men: a population-based study. Cancer. 101:51–57. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Iredale R, Brain K, Williams B, France E and Gray J: The experiences of men with breast cancer in the United Kingdom. Eur J Cancer. 42:334–341. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Nass SJ and Davidson NE: The biology of breast cancer. Hematol Oncol Clin North Am. 13:311–332. 1999. View Article : Google Scholar | |
|
Antonova L, Aronson K and Mueller CR: Stress and breast cancer: from epidemiology to molecular biology. Breast Cancer Res. 13:2082010. View Article : Google Scholar : PubMed/NCBI | |
|
McTiernan A: Behavioral risk factors in breast cancer: can risk be modified? Oncologist. 8:326–334. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Friedenreich CM, Courneya KS and Bryant HE: Influence of physical activity in different age and life periods on the risk of breast cancer. Epidemiology. 12:604–612. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, et al: Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 4:e78872009. View Article : Google Scholar : PubMed/NCBI | |
|
Martin AM and Weber BL: Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 92:1126–1135. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Plak K, Czarnecka AM, Krawczyk T, Golik P and Bartnik E: Breast cancer as a mitochondrial disorder (Review). Oncol Rep. 21:845–851. 2009.PubMed/NCBI | |
|
Lynch HT, Silva E, Snyder C and Lynch JF: Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J. 14:3–13. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Singletary SE: Rating the risk factors for breast cancer. Ann Surg. 237:474–482. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D and Peretz T: Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet. 44:467–471. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Campeau PM, Foulkes WD and Tischkowitz MD: Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 124:31–42. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
King MC, Marks JH and Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302:643–646. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Thorslund T and West SC: BRCA2: a universal recombinase regulator. Oncogene. 26:7720–7730. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Welcsh PL and King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 10:705–713. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Narod SA and Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 4:665–676. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Thorslund T, Esashi F and West SC: Interactions between human BRCA2 protein and the meiosis-specific recombinase DMC1. EMBO J. 26:2915–2922. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Verhoog LC, Berns EM, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ and Klijn JG: Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol. 18:119S–124S. 2000.PubMed/NCBI | |
|
Loman N, Johannsson O, Bendahl P, Dahl N, Einbeigi Z, Gerdes A, Borg A and Olsson H: Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer. 36:1365–1373. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lim LY, Vidnovic N, Ellisen LW and Leong CO: Mutant p53 mediates survival of breast cancer cells. Br J Cancer. 101:1606–1612. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, et al: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 3:387–402. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA and Borresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2505–2512. 2001.PubMed/NCBI | |
|
Beroud C and Soussi T: p53 gene mutation: software and database. Nucleic Acids Res. 26:200–204. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar | |
|
Olivier M, Petitjean A, Marcel V, Petre A, Mounawar M, Plymoth A, de Fromentel CC and Hainaut P: Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 16:1–12. 2009. View Article : Google Scholar | |
|
Hohenstein P and Giles RH: BRCA1: a scaffold for p53 response? Trends Genet. 19:489–494. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de The H and Pusztai L: Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res. 17:2591–2601. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S and Iwase H: Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res. 6:R24–30. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Feki A and Irminger-Finger I: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol. 52:103–116. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Ren Y, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T and Dai F: PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol. 136:1303–1311. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wallace JA, Li F, Leone G and Ostrowski MC: Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution. Cancer Res. 71:1203–1207. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y and Maehara Y: Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat. 101:249–257. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdes A, Gestraud P, et al: Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 10:R1012008. View Article : Google Scholar : PubMed/NCBI | |
|
Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB and Hidalgo M: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol. 15:1510–1516. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Tate G, Suzuki T and Mitsuya T: Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet. 178:160–162. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Petrocelli T and Slingerland JM: PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res. 3:356–360. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JS, Kim HS, Kim YB, Lee MC, Park CS and Min KW: Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast. Appl Immunohistochem Mol Morphol. 12:205–210. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, et al: Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 27:4086–4095. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka M, Koul D, Davies MA, Liebert M, Steck PA and Grossman HB: MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene. 19:5406–5412. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Bates RC, Edwards NS, Burns GF and Fisher DE: A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 61:5275–5283. 2001.PubMed/NCBI | |
|
Nevanlinna H and Bartek J: The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 25:5912–5919. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, et al: Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet. 14:555–563. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Abraham RT: PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways. DNA Repair. 3:883–887. 2004. | |
|
Angele S, Romestaing P, Moullan N, Vuillaume M, Chapot B, Friesen M, Jongmans W, Cox DG, Pisani P, Gerard JP and Hall J: ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 63:8717–8725. 2003.PubMed/NCBI | |
|
McKinnon PJ: ATM and ataxia telangiectasia. EMBO Rep. 5:772–776. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Milne RL: Variants in the ATM gene and breast cancer susceptibility. Genome Med. 1:122009. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JH and Paull TT: Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science. 304:93–96. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Consortium TCBCC-C: CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 74:1175–1182. 2004. | |
|
Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, et al: CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer. 111:543–547. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kleibl Z, Havranek O, Novotny J, Kleiblova P, Soucek P and Pohlreich P: Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations. Breast Cancer Res Treat. 112:159–164. 2008. View Article : Google Scholar | |
|
Le GM, O’Malley CD, Glaser SL, Lynch CF, Stanford JL, Keegan TH and West DW: Breast implants following mastectomy in women with early-stage breast cancer: prevalence and impact on survival. Breast Cancer Res. 7:R184–193. 2005.PubMed/NCBI | |
|
Brown SL: Epidemiology of silicone-gel breast implants. Epidemiology. 13:S34–39. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bese NS, Kiel K, El-Gueddari Bel K, Campbell OB, Awuah B and Vikram B: Radiotherapy for breast cancer in countries with limited resources: program implementation and evidence-based recommendations. Breast J. 12:S96–102. 2006.PubMed/NCBI | |
|
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 97:1262–1271. 2005. View Article : Google Scholar | |
|
Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A and Hershman DL: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 25:3877–3883. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zoli W, Ulivi P, Tesei A, Fabbri F, Rosetti M, Maltoni R, Giunchi DC, Ricotti L, Brigliadori G, Vannini I and Amadori D: Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res. 7:R681–689. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L and Hudis CA: Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 117:5461–5468. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Piccart M: The role of taxanes in the adjuvant treatment of early stage breast cancer. Breast Cancer Res Treat. 79(Suppl 1): S25–34. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC and Norton L: Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 21:1825–1835. 2003. | |
|
Hedley D, Ogilvie L and Springer C: Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer. 7:870–879. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Nishiyama Y and Kikkawa F: Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer? Anticancer Agents Med Chem. 8:232–239. 2008. View Article : Google Scholar | |
|
Greco O and Dachs GU: Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol. 187:22–36. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
McKeown SR, Ward C and Robson T: Gene-directed enzyme prodrug therapy: a current assessment. Curr Opin Mol Ther. 6:421–435. 2004.PubMed/NCBI | |
|
Voeks D, Martiniello-Wilks R, Madden V, Smith K, Bennetts E, Both GW and Russell PJ: Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 9:759–768. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson WF: Gene therapy scores against cancer. Nat Med. 6:862–863. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Chung-Faye GA, Kerr DJ, Young LS and Searle PF: Gene therapy strategies for colon cancer. Mol Med Today. 6:82–87. 2000. View Article : Google Scholar | |
|
Schepelmann S, Hallenbeck P, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Hay C, Hawkins LK, Marais R and Springer CJ: Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res. 65:5003–5008. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF and Kerr DJ: In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 8:1547–1554. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hernandez-Alcoceba R, Sangro B and Prieto J: Gene therapy of liver cancer. World J Gastroenterol. 12:6085–6097. 2006. | |
|
Yi BR, O SN, Kang NH, Hwang KA, Kim SU, Jeung EB, Kim YB, Heo GJ and Choi KC: Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects. Int J Oncol. 39:833–839. 2011. | |
|
Yi BR, Kang NH, Hwang KA, Kim SU, Jeung EB and Choi KC: Antitumor therapeutic effects of cytosine deaminase and interferon-β against endometrial cancer cells using genetically engineered stem cells in vitro. Anticancer Res. 31:2853–2861. 2011. | |
|
Dachs GU, Hunt MA, Syddall S, Singleton DC and Patterson AV: Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules. 14:4517–4545. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pfeifer A and Verma IM: Gene therapy: promises and problems. Annu Rev Genomics Hum Genet. 2:177–211. 2001. View Article : Google Scholar | |
|
Shah K: Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 64:739–748. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ramnaraine M, Pan W, Goblirsch M, Lynch C, Lewis V, Orchard P, Mantyh P and Clohisy DR: Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res. 63:6847–6854. 2003.PubMed/NCBI | |
|
Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, Rehemtulla A and Lawrence TS: The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther. 9:844–849. 2002.PubMed/NCBI | |
|
Ireton GC, Black ME and Stoddard BL: Crystallization and preliminary X-ray analysis of bacterial cytosine deaminase. Acta Crystallogr D Biol Crystallogr. 57:1643–1645. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ireton GC, Black ME and Stoddard BL: The 1.14 A crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy. Structure. 11:961–972. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Denny WA: Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). J Biomed Biotechnol. 2003:48–70. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ireton GC, McDermott G, Black ME and Stoddard BL: The structure of Escherichia coli cytosine deaminase. J Mol Biol. 315:687–697. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchita M, Ardiani A, Zhao L, Serve K, Stoddard BL and Black ME: Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res. 69:4791–4799. 2009. View Article : Google Scholar | |
|
Kim KY, Kim SU, Leung PC, Jeung EB and Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci. 101:955–962. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen JK, Hu LJ, Wang D, Lamborn KR and Deen DF: Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. Int J Radiat Oncol Biol Phys. 67:1538–1547. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Miller CR, Williams CR, Buchsbaum DJ and Gillespie GY: Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 62:773–780. 2002.PubMed/NCBI | |
|
Humerickhouse R, Lohrbach K, Li L, Bosron WF and Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60:1189–1192. 2000.PubMed/NCBI | |
|
Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM and Redinbo MR: Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol. 9:337–342. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Bodor N and Buchwald P: Soft drug design: general principles and recent applications. Med Res Rev. 20:58–101. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Wadkins RM, Morton CL, Weeks JK, Oliver L, Wierdl M, Danks MK and Potter PM: Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol Pharmacol. 60:355–362. 2001.PubMed/NCBI | |
|
Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC and Potter PM: Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res. 61:5078–5082. 2001.PubMed/NCBI | |
|
Kojima A, Hackett NR, Ohwada A and Crystal RG: In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest. 101:1789–1796. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF and Hospers GA: Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther. 2:307–322. 2002.PubMed/NCBI | |
|
Gerolami R, Cardoso J, Lewin M, Bralet MP, Sa Cunha A, Clement O, Brechot C and Tran PL: Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes. Cancer Res. 60:993–1001. 2000.PubMed/NCBI | |
|
Fillat C, Carrio M, Cascante A and Sangro B: Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 3:13–26. 2003.PubMed/NCBI | |
|
Huang Q, Pu P, Xia Z and You Y: Exogenous wt-p53 enhances the antitumor effect of HSV-TK/GCV on C6 glioma cells. J Neurooncol. 82:239–248. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cowen RL, Williams JC, Emery S, Blakey D, Darling JL, Lowenstein PR and Castro MG: Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cancer Gene Ther. 9:897–907. 2002. View Article : Google Scholar | |
|
Muller FJ, Snyder EY and Loring JF: Gene therapy: can neural stem cells deliver? Nat Rev Neurosci. 7:75–84. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SU, Jeung EB, Kim YB, Cho MH and Choi KC: Potential tumor-tropic effect of genetically engineered stem cells expressing suicide enzymes to selectively target invasive cancer in animal models. Anticancer Res. 31:1249–1258. 2011. | |
|
Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X and Weissleder R: In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther. 14:1247–1254. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Power AT and Bell JC: Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther. 15:660–665. 2007.PubMed/NCBI | |
|
Kim KY, Yi BR, Lee HR, Kang NH, Jeung EB, Kim SU and Choi KC: Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use. Int J Oncol. 40:1097–1104. 2012.PubMed/NCBI | |
|
Aboody KS, Najbauer J and Danks MK: Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 15:739–752. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ, Guevorkian M, Edmiston M, Zhao D, Glackin CA, et al: Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells. 26:1406–1413. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bithell A and Williams BP: Neural stem cells and cell replacement therapy: making the right cells. Clin Sci. 108:13–22. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SK, Kim SU, Park IH, Bang JH, Aboody KS, Wang KC, Cho BK, Kim M, Menon LG, Black PM and Carroll RS: Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res. 12:5550–5556. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sohur US, Emsley JG, Mitchell BD and Macklis JD: Adult neurogenesis and cellular brain repair with neural progenitors, precursors and stem cells. Philos Trans R Soc Lond B Biol Sci. 361:1477–1497. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SU, Park IH, Kim TH, Kim KS, Choi HB, Hong SH, Bang JH, Lee MA, Joo IS, Lee CS and Kim YS: Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology. 26:129–140. 2006. View Article : Google Scholar | |
|
Joo KM, Park IH, Shin JY, Jin J, Kang BG, Kim MH, Lee SJ, Jo MY, Kim SU and Nam DH: Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther. 17:570–575. 2009. View Article : Google Scholar : PubMed/NCBI |
